within Pharmacolibrary.Drugs.ATC.G;

model G03AA12
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.76,
    Cl             = 2.5e-05,
    adminDuration  = 600,
    adminMass      = 3 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.004,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.02,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.007,
    k12             = 0.83,
    k21             = 0.83
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G03AA12</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Drospirenone and ethinylestradiol is a combined oral contraceptive containing a progestin (drospirenone) and an estrogen (ethinylestradiol). It is used to prevent pregnancy and is also indicated for the treatment of moderate acne and premenstrual dysphoric disorder in women who use oral contraceptives. The combination is widely approved and used globally.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy female adults after single or multiple oral administrations.</p><h4>References</h4><ol><li><p>Blode, H, et al., &amp; Diefenbach, K (2012). Bioequivalence study of an oral contraceptive containing ethinylestradiol/drospirenone/levomefolate calcium relative to ethinylestradiol/drospirenone and to levomefolate calcium alone. <i>Contraception</i> 85(2) 177–184. DOI:<a href=\"https://doi.org/10.1016/j.contraception.2011.05.015\">10.1016/j.contraception.2011.05.015</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22067789/\">https://pubmed.ncbi.nlm.nih.gov/22067789</a></p></li><li><p>Suhas, S, et al., &amp; Kumar, V (2021). Clozapine and Oral Contraceptives-Implications Beyond Pharmacokinetics: A Case Report. <i>Journal of clinical psychopharmacology</i> 41(4) 487–490. DOI:<a href=\"https://doi.org/10.1097/JCP.0000000000001415\">10.1097/JCP.0000000000001415</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34166256/\">https://pubmed.ncbi.nlm.nih.gov/34166256</a></p></li><li><p>Zimmerman, Y, et al., &amp; Coelingh Bennink, HJ (2013). The bioequivalence of the contraceptive steroids ethinylestradiol and drospirenone is not affected by co-administration of dehydroepiandrosterone. <i>The European journal of contraception &amp; reproductive health care : the official journal of the European Society of Contraception</i> 18(3) 206–214. DOI:<a href=\"https://doi.org/10.3109/13625187.2013.777831\">10.3109/13625187.2013.777831</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23550808/\">https://pubmed.ncbi.nlm.nih.gov/23550808</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G03AA12;
